SCHEMBL360467

SCHEMBL360467

COCCOc1ccnc2ccc(Br)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAK O14976 2/20 0.47
EPHB6 O15197 1/20 0.47
RIPK2 O43353 1/20 0.47
STK16 O75716 1/20 0.47
ABL1 P00519 1/20 0.47
ACVR1 Q04771 1/20 0.47
AAK1 Q2M2I8 1/20 0.47
COQ8A Q8NI60 1/20 0.47
NLK Q9UBE8 1/20 0.47
FBP1 P09467 2/20 0.44
SLC22A12 Q96S37 3/20 0.43
EGFR P00533 2/20 0.43
ALDH1A1 P00352 2/20 0.43
PDGFRB P09619 3/20 0.40
CCNC P24863 2/20 0.40
CDK8 P49336 2/20 0.40
NCF1 P14598 1/20 0.40
HTT P42858 2/20 0.39
DYRK1A Q13627 1/20 0.39
ERBB2 P04626 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10283762 0.85 NCF1 (0.43) GAKEPHB6RIPK2STK16ABL1
SCHEMBL12390292 0.85 PDGFRB (0.54) GAKEPHB6RIPK2STK16ABL1
SCHEMBL358762 0.84 GAK (0.61) GAKEPHB6RIPK2STK16ABL1
SCHEMBL4079743 0.83 LMNA (0.46) GAKEPHB6RIPK2STK16ABL1
SCHEMBL2621790 0.83 PDGFRB (0.50) GAKEPHB6RIPK2STK16ABL1
SCHEMBL2621792 0.82 HTR7 (0.45) GAKEPHB6RIPK2STK16ABL1
SCHEMBL2621799 0.82 GAK (0.43) GAKEPHB6RIPK2STK16ABL1
SCHEMBL22122413 0.82 SLC22A12 (0.42) GAKEPHB6RIPK2STK16ABL1
SCHEMBL2621787 0.81 CYP1A2 (0.47) GAKEPHB6RIPK2STK16ABL1
SCHEMBL2621793 0.81 SLC22A12 (0.47) GAKEPHB6RIPK2STK16ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593107-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-05-22 EP disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116231-A1 TYROSINE KINASE INHIBITORS ABL1, ERBB2, MET GAK 366/4885EPHB6 691/4885RIPK2 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.